신경계 의약품 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of neurology drugs Market

The global neurology drugs market is experiencing significant growth due to the rising burden of neurological disorders and increasing advancements in pharmaceutical research. The market was valued at USD 160.51 billion in 2025 and is projected to grow to USD 173.70 billion in 2026, reaching USD 267.15 billion by 2034, exhibiting a CAGR of 9.10% during the forecast period (2026-2034).

North America dominated the market in 2025, supported by strong healthcare infrastructure, high disease prevalence, and robust research and development activities.

Neurology drugs are used to treat a wide range of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis. Increasing awareness, improved diagnosis rates, and expanding treatment options are contributing to market expansion.

Market Dynamics

Market Drivers

The increasing prevalence of neurological disorders is a major factor driving market growth. According to global health estimates, neurological conditions affect a significant portion of the population, creating strong demand for effective treatment options.

The growing aging population is another key contributor, as elderly individuals are more prone to neurodegenerative diseases. Additionally, rising investments in research and development for innovative therapies, including biologics and gene-based treatments, are accelerating market growth.

Market Restraints

Despite strong growth prospects, the high cost of neurological treatments remains a major challenge. Drug development involves extensive clinical trials and regulatory approvals, making therapies expensive and limiting accessibility for patients.

High out-of-pocket healthcare expenses and affordability issues, especially in developing regions, further restrain market growth.

Market Trends

Technological advancements are transforming the neurology drugs market. Innovations such as artificial intelligence, brain-computer interfaces, and advanced neuroimaging techniques are improving diagnosis and treatment outcomes.

Another key trend is the rise of biologics and monoclonal therapies, which offer targeted treatment with fewer side effects. These therapies are increasingly used in managing complex neurological disorders.

Additionally, the growing adoption of personalized medicine is reshaping treatment approaches, enabling customized therapies based on individual patient profiles.

Market Opportunities and Challenges

The increasing focus on personalized medicine presents significant opportunities for market players. Tailored treatments improve patient outcomes and treatment adherence, enhancing overall healthcare efficiency.

However, the complexity of neurological disorders poses a major challenge. These conditions are difficult to diagnose and treat due to varying patient responses and limited understanding of disease mechanisms. Drug delivery to the brain also remains a scientific hurdle, impacting treatment effectiveness.

Segmentation Analysis

By Indication

The market is segmented into Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and others. The Alzheimer's disease segment is expected to dominate due to increasing prevalence and rising awareness initiatives.

By Drug Class

Based on drug class, the market includes cholinesterase inhibitors, NMDA receptor antagonists, antiepileptic drugs, and immunomodulatory drugs. The cholinesterase inhibitors segment is anticipated to lead due to high usage and recent product approvals.

By Route of Administration

The market is divided into oral and parenteral routes. The oral segment dominates due to ease of administration and high patient compliance, while parenteral drugs are expected to grow steadily.

By Distribution Channel

Hospital pharmacies hold the largest market share due to high patient inflow and prescription-based drug distribution. Retail and online pharmacies are also witnessing steady growth.

Regional Insights

North America

North America remains the leading region, with a market size of USD 91.68 billion in 2025, projected to reach USD 99.39 billion in 2026. Strong research infrastructure and high adoption of innovative therapies drive growth.

Europe

Europe accounted for USD 44.70 billion in 2025 and is expected to reach USD 48.30 billion in 2026, supported by increasing awareness programs and advanced healthcare systems.

Asia Pacific

Asia Pacific reached USD 29.78 billion in 2025 and is projected to grow to USD 32.73 billion in 2026, driven by improving healthcare access and rising patient populations.

Latin America & Middle East & Africa

These regions are gradually expanding due to improving healthcare infrastructure, increasing disease awareness, and government initiatives.

Competitive Landscape

The neurology drugs market is highly competitive, with major players focusing on innovation and expanding their product portfolios. Key companies include:

• Novartis AG
• Bayer AG
• Pfizer Inc.
• Sanofi
• Biogen Inc.
• Johnson & Johnson Services, Inc.
• Merck KGaA

These companies are investing heavily in research and strategic collaborations to strengthen their market position.

Key Industry Developments

• May 2025: Sanofi acquired Vigil Neuroscience to expand its neurology pipeline.
• October 2024: Fast Track designation granted for a new therapy targeting Alexander disease.
• September 2024: Approval of a novel drug for Niemann-Pick disease type C.
• February 2024: Launch of advanced multiple sclerosis therapy in India.

Conclusion

The global neurology drugs market is poised for strong growth, driven by increasing prevalence of neurological disorders, advancements in drug development, and rising demand for personalized medicine. While high treatment costs and disease complexity present challenges, ongoing innovation and expanding healthcare access are expected to drive long-term market expansion. As pharmaceutical companies continue to invest in cutting-edge therapies, the market will play a crucial role in improving patient outcomes and addressing the global burden of neurological diseases.

Segmentation By Indication

• Alzheimer's Disease
• Multiple Sclerosis
• Epilepsy
• Parkinson's Disease
• Others

By Drug Class

• Cholinesterase Inhibitors
• NMDA Receptor Antagonist
• Antiepileptic Drugs
• Immunomodulatory Drugs
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Region

• North America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • U.S.
  • Canada
• Europe (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Neurological Disorders, By Key Countries/Regions
• 4.2. Regulatory Framework, By Key Countries/Regions
• 4.3. Reimbursement Scenario, By Key Countries/Regions
• 4.4. New Product Launches & Approvals, By Key Players
• 4.5. Key Industry Developments (Merger, Acquisition, Collaboration, etc.)

5. Global Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Indication
  • 5.1.1. Alzheimer's Disease
  • 5.1.2. Moltiple Sclerosis
  • 5.1.3. Epilepsy
  • 5.1.4. Parkinson's Disease
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Cholinesterase Inhibitors
  • 5.2.2. NMDA Receptor Antagonist
  • 5.2.3. Antiepileptic Drugs
  • 5.2.4. Immunomodolatory Drugs
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies & Drug Stores
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Indication
  • 6.1.1. Alzheimer's Disease
  • 6.1.2. Moltiple Sclerosis
  • 6.1.3. Epilepsy
  • 6.1.4. Parkinson's Disease
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Cholinesterase Inhibitors
  • 6.2.2. NMDA Receptor Antagonist
  • 6.2.3. Antiepileptic Drugs
  • 6.2.4. Immunomodolatory Drugs
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies & Drug Stores
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Indication
  • 7.1.1. Alzheimer's Disease
  • 7.1.2. Moltiple Sclerosis
  • 7.1.3. Epilepsy
  • 7.1.4. Parkinson's Disease
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Cholinesterase Inhibitors
  • 7.2.2. NMDA Receptor Antagonist
  • 7.2.3. Antiepileptic Drugs
  • 7.2.4. Immunomodolatory Drugs
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies & Drug Stores
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Indication
  • 8.1.1. Alzheimer's Disease
  • 8.1.2. Moltiple Sclerosis
  • 8.1.3. Epilepsy
  • 8.1.4. Parkinson's Disease
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Cholinesterase Inhibitors
  • 8.2.2. NMDA Receptor Antagonist
  • 8.2.3. Antiepileptic Drugs
  • 8.2.4. Immunomodolatory Drugs
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies & Drug Stores
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.5.1. China
  • 8.5.2. India
  • 8.5.3. Japan
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Indication
  • 9.1.1. Alzheimer's Disease
  • 9.1.2. Moltiple Sclerosis
  • 9.1.3. Epilepsy
  • 9.1.4. Parkinson's Disease
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Cholinesterase Inhibitors
  • 9.2.2. NMDA Receptor Antagonist
  • 9.2.3. Antiepileptic Drugs
  • 9.2.4. Immunomodolatory Drugs
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies & Drug Stores
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Indication
  • 10.1.1. Alzheimer's Disease
  • 10.1.2. Moltiple Sclerosis
  • 10.1.3. Epilepsy
  • 10.1.4. Parkinson's Disease
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Cholinesterase Inhibitors
  • 10.2.2. NMDA Receptor Antagonist
  • 10.2.3. Antiepileptic Drugs
  • 10.2.4. Immunomodolatory Drugs
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Parenteral
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies & Drug Stores
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.5.1. South Africa
  • 10.5.2. GCC
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Eisai Co., Ltd.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. Financials (Based on Availability)
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. SWOT, etc.
  • 11.2.2. Strategies
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. Financials (Based on Availability)
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. SWOT, etc.
  • 11.2.3. Biogen Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. Financials (Based on Availability)
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. SWOT, etc.
  • 11.2.4. Bayer AG
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. Financials (Based on Availability)
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. SWOT, etc.
  • 11.2.5. Pfizer Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. Financials (Based on Availability)
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. SWOT, etc.
  • 11.2.6. Johnson & Johnson Services, Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. Financials (Based on Availability)
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. SWOT, etc.
  • 11.2.7. Novartis AG
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. Financials (Based on Availability)
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. SWOT, etc.
  • 11.2.8. Merck KGaA
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. Financials (Based on Availability)
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. SWOT, etc.
  • 11.2.9. Sanofi
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. Financials (Based on Availability)
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. SWOT, etc.
  • 11.2.10. AbbVie Inc.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. Financials (Based on Availability)
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. SWOT, etc.